A. Harlow

发表

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

C. Antonescu, J. Fletcher, G. Demetri, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

sensitive subsets tipifarnib: identification of T-cell ALL and FAB M5 AML as the most In vitro profiling of the sensitivity of pediatric leukemia cells to

M. Heinrich, A. Harlow, D. Reinhardt, 2013 .

In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.

M. Heinrich, A. Harlow, D. Reinhardt, 2005, Blood.

Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia

J. Berkhof, Q. Waisfisz, M. Heinrich, 2009, Haematologica.

KIT Gene Mutations and Copy Number in Melanoma Subtypes

Susan Muller, Janice Patterson, R. West, 2008, Clinical Cancer Research.

Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.

J. Fletcher, M. Heinrich, C. Corless, 2007, Cancer research.

Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia

S. Meshinchi, M. Heinrich, A. Harlow, 2005, Leukemia.

Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.

Laura J. Winter, B. Druker, M. Heinrich, 2011, The Journal of molecular diagnostics : JMD.

An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia

B. Druker, M. Heinrich, C. Corless, 2008, Leukemia.

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

Heikki Joensuu, Richard Herrmann, J. Fletcher, 2008, Clinical Cancer Research.

Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer

Kwok-Kin Wong, R. Kurek, C. Bokemeyer, 2009, Molecular Cancer Therapeutics.

Copy Number in Melanoma Subtypes

R. West, M. Heinrich, C. Corless, 2008 .

Subtypes Gene Mutations and Copy Number in Melanoma

R. West, M. Heinrich, C. Corless, 2008 .

Mechanisms of sunitinib malate (SU) resistance in gastrointestinal stromal tumors (GISTs)

M. Bertagnolli, J. Fletcher, G. Demetri, 2007 .

An Activating KRAS Mutation in Imatinib Resistant Chronic Myeloid Leukemia.

B. Druker, M. Heinrich, C. Corless, 2007 .